Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Inclusion Criteria: * adenocarcinoma breast cancer * ECOG performance status of 0 or 1 * peripheral neuropathy less than or equal to 1 * discontinued hormonal therapy as a chemoprevention while onstudy * LVEF by MUGA \> 55%? * Absolute neutrophil count (ANC)\> 1000/µL) * platelet count \> 100,000/µL) * SGOT OR SGPT \< 92.5 units/L Exclusion Criteria: * Stage IV breast cancer * any chemotherapy, radiation therapy, immunotherapy, or biotherapy for a CURRENT breast cancer * pregnant or lactating patients * active second malignancy, other than adequately treated non-melanoma skin cancers or in situ cervical cancer * previous allergy/hypersensitivity to Doxorubicin, Cyclophosphamide, Paclitaxel, or other drugs formulated in Cremophor EL? * unstable angina, congestive heart failure, current use of digitalis, beta-blockers, or calcium blockers for therapy of congestive heart failure, arrhythmia requiring medical therapy, or a history of a myocardial infarction within 12 months * psychiatric illness that prevents her from understanding the nature of this study and complying with protocol requirements? * active, unresolved infections * sensitivity to E. coli derived proteins * prior chemotherapy with an anthracycline * prior Herceptin therapy